肝癌转化治疗中仑伐替尼耐药机制的研究进展-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

肝癌转化治疗中仑伐替尼耐药机制的研究进展

Research advances in the mechanisms of Lenvatinib resistance in hepatocellular carcinoma conversion therapy

ES评分 0 浏览量：44 下载量：0

DOI	10.12208/j.ijcr.20250228
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2025, 9(5)
作者	李澎钺,傅华*,
作者单位	承德医学院附属医院河北承德
摘要	肝细胞癌（HCC）是我国癌症相关死亡的主要原因之一，多数患者确诊时已处于中晚期，丧失手术机会。转化治疗通过靶向、免疫及局部治疗联合策略，使不可切除肝癌降期，为患者争取手术可能。其中，仑伐替尼等靶向药物联合免疫治疗显著提高了客观缓解率，但耐药机制（如EGFR、VEGFR、FGFR及Wnt/β-catenin通路异常）仍制约疗效。未来需探索多学科联合策略，克服耐药并优化个体化治疗，以改善患者预后。
Abstract	Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in China, with most patients diagnosed at advanced stages and thus ineligible for surgical resection. Conversion therapy, employing combined strategies of targeted therapy, immunotherapy, and local treatment, enables tumor downstaging in initially unresectable HCC, potentially rendering patients eligible for curative surgery. Notably, lenvatinib-based targeted therapy combined with immunotherapy has significantly improved objective response rates. However, resistance mechanisms—including dysregulation of EGFR, VEGFR, FGFR, and Wnt/β-catenin signaling pathways—remain a major therapeutic limitation. Future research should focus on multidisciplinary strategies to overcome drug resistance and optimize personalized treatment, thereby improving patient outcomes.
关键词	肝细胞癌；耐药；仑伐替尼
KeyWord	HCC; Resistance; Lenvatinib
基金项目
页码	28-31

参考文献
相关文献

[1] Han BF, Zheng RS, Zeng HM, et al. Cancer incidence and mortality in China, 2022
[J].Journal of the National Cancer Center.
[2] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南（2024年版）
[J]. 临床肝胆病杂志, 2024,40(5).893-918.
[3] 中国抗癌协会肝癌专业委员会转化治疗协作组. 原发性肝癌转化及围手术期治疗中国专家共识（2024版）
[J]. 中华消化外科杂志, 2024,23(4):492-513.
[4] Reig M, Forner A, Rimola J, 等. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
[J]. Journal of hepatology, 2022, 76(3): 681-693.
[5] 陈琪栋, 梁军波. 肝细胞癌根治性切除术后无复发生存时间和总生存的影响因素
[J]. 临床医学进展, 2024,14(4): 2268-2273.
[6] Zhang W, Liu C, Tan YF, et al. Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study
[J]. Int J Surg, 2018, 54(Pt A): 259-264.
[7] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)
[J].中华消化外科杂志，2020, 19(1):1-20.
[8] 李雪瑞, 李俊锋, 张雯雯, 等. 免疫联合靶向序贯外科根治性手术方案治疗初始不可切除肝细胞癌的远期疗效
[J]. 中华肝胆外科杂志, 2024,30(1):9-14.
[9] 中华预防医学会肝胆胰疾病预防与控制专业委员会，中国抗癌协会肝癌专业委员会，北京医学会外科学分会肝脏学组等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)
[J].中华肝胆外科杂志，2021,27(4):241-251.
[10] Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations
[J]. Liver Cancer, 2021,10(4):320-329.
[11] Park J.W., Chen M., Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study
[J]. Liver Int, 2015,35:2155–2166.
[12] Fan W, Zhu B, Chen S, et al. Kuang M, Peng Z. Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial
[J]. JAMA Oncol, 2024,10(8):1047-1054.
[13] LIU JF, LI Z, ZHANG WG, et al. Comprehensive treatment of trans-arterial chemoembolization plus lenvatinib followed by camrelizumab for advanced hepatocellular carcinoma patients
[J]. Front Pharmacol, 2021, 12:709060.
[14] KE Q, XIN FL, FANG HP, et al. The significance of transarterial chemo(embolization)combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma in the era of systemic therapy:A systematic review
[J]. Front Immunol, 2022, 13:913464.
[15] MATSUKI M, HOSHI T, YAMAMOTO Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
[J]. Cancer Med, 2018, 7(6):2641-2653.
[16] Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
[J]. Cancer Sci, 2018,109(12):3993-4002.
[17] Kudo M, Finn R S, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
[J]. Lancet, 2018,391(10126):1163-1173.
[18] Qin Y, Han S, Yu Y, et al. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
[J]. Liver Int, 2024,44(8):1808-1831.
[19] Bai X, Sun P, Wang X, Long C, Liao S, Dang S, Zhuang S, Du Y, Zhang X, Li N, He K, Zhang Z. Structure and dynamics of the EGFR/HER2 heterodimer
[J]. Cell Discov, 2023, 9(1): 18.
[20] Jin HJ, Shi YP, LV YY, et al. EGFR activation limits the response of liver cancer to lenvatinib
[J]. Nature, 2021, 595(7869):730-734.
[21] 蒋文军.LINC00511与血管内皮生长因子受体VEGFR1和VEGFR2促进三阴性乳腺癌肿瘤血管生成及其临床相关性研究
[D].右江民族医学院,2024.
[22] Zhao ZW, Zhang DK, Wu FZ, et al. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression
[J]. J Cell Mol Med, 2021, 25(1):549-560.
[23] BYRON SA, CHEN HB, WORTMANN A, et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib,and ponatinib ATP-competitive inhibitors
[J]. Neoplasia, 2013, 15(8):975-988.
[24] 陈锦浩,曹智,陈家诚,等.Wnt/β-catenin通路调控铁死亡在肝癌中的研究进展
[J].海南医学院学报,2024,30(14):1104-1110.
[25] 陈家诚,刘路政,陈良,等.肝癌细胞仑伐替尼耐药的基因筛选及其通路研究
[J].肝胆胰外科杂志,2022,34(03):157-163.
[26] GUO YR, XU J, DU Q, et al. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma(HCC)through regulating β-catenin
[J]. Transl Oncol, 2021, 14(6):101059.
[27] Wang JH, Yu HM, Dong W, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells’ properties and lenvatinib resistance through WNT/β-catenin and hippo signaling pathways
[J]. Gastroenterology, 2023, 164(6):990-1005.

引用本文

李澎钺,傅华*. 肝癌转化治疗中仑伐替尼耐药机制的研究进展 [J]. 国际临床研究杂志. 2025; 9; (5). 28 - 31.

文献评论

相关学者

相关机构